Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory, and autoimmune diseases. Founded in 2015, the company leverages its deep expertise in the ATP-adenosine pathway and other key biological mechanisms to create a robust pipeline of small molecules and monoclonal antibodies. The company is characterized by its strategic 10-year collaboration with Gilead Sciences, which includes significant equity investment and co-development rights. Arcus is currently advancing several late-stage programs, including anti-TIGIT and HIF-2α inhibitors, aiming to establish first- or best-in-class treatments across multiple solid tumor indications such as lung, gastrointestinal, and renal cell cancers.